U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07544953) titled 'Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology' on Dec. 21, 2025.
Brief Summary: This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology. Lecanemab, an anti-amyloid monoclonal antibody, was apporoved by the US FDA in July 2023 and in South Korea in May 2024, as a disease-modifying therapy based on its clinical efficacy and reduction of amyloid plaques in patients with early-stage Alzheimer's disease (AD). AD pathology is also common in PD, and approximately 35% of patients with PD dementia have co-existing AD ...